Should African Americans with Hypertension Be Treated Differently than Non-African Americans?

被引:0
作者
John M. Flack
Brian A. Ference
Phillip Levy
机构
[1] Wayne State University,Division of Translational Research and Clinical Epidemiology, Department of Medicine
[2] Wayne State University,Division of Endocrinology, Metabolism, and Hypertension, Department of Medicine
[3] Wayne State University,Department of Physiology
[4] Wayne State University,Department of Medicine, Division of Translational Research and Clinical Epidemiology
[5] Wayne State University,Division of Cardiology, Department of Medicine
[6] Wayne State University,Department of Emergency Medicine, Department of Medicine
来源
Current Hypertension Reports | 2014年 / 16卷
关键词
Hypertension; Blood pressure (BP) target; Diabetes; Chronic kidney disease; CKD; African Americans; Prevention; Treatment; Cardiovascular disease; CVD;
D O I
暂无
中图分类号
学科分类号
摘要
African Americans have a higher burden of hypertension, more severe blood pressure (BP) elevations, more concurrent risk-enhancing co-morbidities (e.g., diabetes), sub-clinical vascular injury at lower non-hypertensive BP levels, lower BP control rates, and significantly greater risk for adverse pressure-related clinical complications (e.g., stroke, heart failure) than whites. Randomized prospective data from hypertension endpoint trials show a virtually identical percentage reduction in CVD risk for a given magnitude of BP lowering, irrespective of the presence or absence of pre-treatment CVD across a broad range of BP down to pre-treatment BP levels of 110/70 mm Hg. These data, mostly emanating from white populations, do not necessarily inform practitioners as to the level below which BP should be lowered in those with established, long-standing hypertension; however, these data do provide support for initiating hypertension treatment at lower than conventional BP thresholds. A Mendelian randomized study examining the impact of life-long lower SBP levels showed that lifelong exposure to 10 mm Hg lower SBP was associated with an 82 % lesser rate of SBP rise per decade and a 58 % lower CHD risk that was much greater than the 22 % reduction in CHD reported for the same magnitude of SBP reduction in clinical trials. Arguably, it is the hypertension treatment paradigm that merits reexamination. Earlier hypertension treatment in all populations prior to the onset of significant pressure-related target organ injury might conceivably prevent, or at least significantly attenuate, the well documented age-related rise in BP seen in most Western societies. In addition, this treatment paradigm might also reduce the significant residual CVD risk observed under the current recommended approach to hypertension treatment. This new approach to therapy would likely have substantial clinical and public health benefits in the high-risk, under-treated African American population that suffers outsized devastating consequences from inadequate control of BP.
引用
收藏
相关论文
共 106 条
[1]  
Stein CM(1997)Vasodilation in black Americans. Attenauted nitric oxide-mediated responses Clin Pharmacol Ther 62 436-43
[2]  
Lang CC(2003)Low arterial compliance in young African American males Am J Physiol Heart Circ Physiol 285 H457-62
[3]  
Nelson R(2008)Racial differences in central blood pressure and vascular function in young men Am J Physiol Heart Circ Physiol 295 H2380-7
[4]  
Brown M(2012)Trends in Prevalence, Awareness, Management, and Control of Hypertension Among United States Adults, 1999 to 2010 J Am Coll Cardiol 60 599-606
[5]  
Wood AJ(2008)Racial disparity in hypertension control: tallying the death toll Am Fam Med 6 497-502
[6]  
Zion AS(2005)State of disparities in cardiovascular health in the United States Circulation 11 1233-41
[7]  
Bond V(2004)Racial differences in the outcomes of patients with diastolic heart failure Am Heart J 1148 151-6
[8]  
Adams RG(1993)Ethnicity and renal disease: lessons from Multiple Risk Factor Intervention Trial and the Treatment of Mild Hypertension Study Am J Kidney Dis 21 31-40
[9]  
Williams RE(2010)Chou C_F, Cotch MF, et al. Prevalence of diabetic retinopathy in the United States, 2005–2008 JAMA 304 649-56
[10]  
Fullilove RP(2012)Impact of blood pressure and blood pressure change during middle age on the remaining lifetime risk for cardiovascular disease: the cardiovascular lifetime risk pooling project Circulation 125 37-44